These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 14754891)

  • 1. "Network leaning" as a mechanism of insurmountable antagonism of the angiotensin II type 1 receptor by non-peptide antagonists.
    Takezako T; Gogonea C; Saad Y; Noda K; Karnik SS
    J Biol Chem; 2004 Apr; 279(15):15248-57. PubMed ID: 14754891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lys(199) mutation of the human angiotensin type 1 receptor differentially affects the binding of surmountable and insurmountable non-peptide antagonists.
    Fierens FL; Vanderheyden PM; Gáborik Z; Minh TL; Backer JP; Hunyady L; Ijzerman A; Vauquelin G
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):283-8. PubMed ID: 11881039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin II type 1 receptor antagonists. Why do some of them produce insurmountable inhibition?
    Vanderheyden PM; Fierens FL; Vauquelin G
    Biochem Pharmacol; 2000 Dec; 60(11):1557-63. PubMed ID: 11077037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the insurmountable angiotensin AT1 receptor antagonist candesartan and the surmountable antagonist losartan on ischemia/reperfusion injury in rat hearts.
    Wang QD; Sjöquist PO
    Eur J Pharmacol; 1999 Sep; 380(1):13-21. PubMed ID: 10513555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type 1 receptors.
    Vanderheyden PM; Fierens FL; De Backer J; Vauquelin G
    Biochem Pharmacol; 2000 Apr; 59(8):927-35. PubMed ID: 10692557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A two-state receptor model for the interaction between angiotensin II type 1 receptors and non-peptide antagonists.
    Vauquelin G; Morsing P; Fierens FL; De Backer JP; Vanderheyden PM
    Biochem Pharmacol; 2001 Feb; 61(3):277-84. PubMed ID: 11172731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insurmountable angiotensin AT1 receptor antagonists: the role of tight antagonist binding.
    Fierens FL; Vanderheyden PM; De Backer JP; Vauquelin G
    Eur J Pharmacol; 1999 May; 372(2):199-206. PubMed ID: 10395100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans.
    Vauquelin G; Fierens F; Van Liefde I
    J Hypertens Suppl; 2006 Mar; 24(1):S23-30. PubMed ID: 16601569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinction between surmountable and insurmountable selective AT1 receptor antagonists by use of CHO-K1 cells expressing human angiotensin II AT1 receptors.
    Vanderheyden PM; Fierens FL; De Backer JP; Fraeyman N; Vauquelin G
    Br J Pharmacol; 1999 Feb; 126(4):1057-65. PubMed ID: 10193788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide and nonpeptide antagonist interaction with constitutively active human AT1 receptors.
    Le MT; Vanderheyden PM; Szaszák M; Hunyady L; Kersemans V; Vauquelin G
    Biochem Pharmacol; 2003 Apr; 65(8):1329-38. PubMed ID: 12694873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BMS-180560, an insurmountable inhibitor of angiotensin II-stimulated responses: comparison with losartan and EXP3174.
    Dickinson KE; Cohen RB; Skwish S; Delaney CL; Serafino RP; Poss MA; Gu Z; Ryono DE; Moreland S; Powell JR
    Br J Pharmacol; 1994 Sep; 113(1):179-89. PubMed ID: 7812609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Binding of KRH-594, an antagonist of the angiotensin II type 1 receptor, to cloned human and rat angiotensin II receptors.
    Inada Y; Nakane T; Chiba S
    Fundam Clin Pharmacol; 2002 Aug; 16(4):317-23. PubMed ID: 12570021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional antagonism of different angiotensin II type I receptor blockers in human arteries.
    Wagenaar LJ; Voors AA; Buikema H; van Buiten A; Lübeck RH; Boonstra PW; van Veldhuisen DJ; van Gilst WH
    Cardiovasc Drugs Ther; 2002 Jul; 16(4):311-6. PubMed ID: 12652100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanistic differences of various AT1-receptor blockers in isolated vessels of different origin.
    Morsing P; Adler G; Brandt-Eliasson U; Karp L; Ohlson K; Renberg L; Sjöquist PO; Abrahamsson T
    Hypertension; 1999 Jun; 33(6):1406-13. PubMed ID: 10373224
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753.
    Wong PC; Timmermans PB
    J Pharmacol Exp Ther; 1991 Jul; 258(1):49-57. PubMed ID: 2072311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist.
    Maillard MP; Perregaux C; Centeno C; Stangier J; Wienen W; Brunner HR; Burnier M
    J Pharmacol Exp Ther; 2002 Sep; 302(3):1089-95. PubMed ID: 12183667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candesartan (CV-11974) dissociates slowly from the angiotensin AT1 receptor.
    Ojima M; Inada Y; Shibouta Y; Wada T; Sanada T; Kubo K; Nishikawa K
    Eur J Pharmacol; 1997 Jan; 319(1):137-46. PubMed ID: 9030909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of angiotensin II antagonism displayed by SK-1080, a novel nonpeptide AT1-receptor antagonist.
    Lee SH; Jung YS; Lee BH; Yun SI; Yoo SE; Shin HS
    J Cardiovasc Pharmacol; 1999 Mar; 33(3):367-74. PubMed ID: 10069670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between the partially insurmountable antagonist valsartan and human recombinant angiotensin II type 1 receptors.
    Verheijen I; Fierens FL; Debacker JP; Vauquelin G; Vanderheyden PM
    Fundam Clin Pharmacol; 2000; 14(6):577-85. PubMed ID: 11206708
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
    Montón M; Jiménez A; Núñez A; López-Blaya A; Farré J; Gómez J; Zalba LR; Sánchez de Miguel L; Casado S; López-Farré A
    J Cardiovasc Pharmacol; 2000 Jun; 35(6):906-13. PubMed ID: 10836725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.